Assessing Interactions for Fixed-dose Drug Combinations in Subcutaneous Tumor Xenograft Studies

Overview

Journal Pharm Stat

Publisher Wiley

Specialties Pharmacology
Public Health

Date 2013 Mar 9

PMID 23471653

Citations 3

Authors

Jianrong Wu

Affiliations

Soon will be listed here.

Abstract

Drug combinations in preclinical tumor xenograft studies are often assessed using fixed doses. Assessing the joint action of drug combinations with fixed doses has not been well developed in the literature. Here, an interaction index is proposed for fixed-dose drug combinations in a subcutaneous tumor xenograft model. Furthermore, a bootstrap percentile interval of the interaction index is also developed. The joint action of two drugs can be assessed on the basis of confidence limits of the interaction index. Tumor xenograft data from actual two-drug combination studies are analyzed to illustrate the proposed method.

Citing Articles

Radius additivity score: a novel combination index for tumour growth inhibition in fixed-dose xenograft studies.

Melillo N, Dickinson J, Tan L, Mistry H, Huber H Front Pharmacol. 2023; 14:1272058.

PMID: 37900154 PMC: 10603293. DOI: 10.3389/fphar.2023.1272058.

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts.

Huang L, Wang J, Fang B, Meric-Bernstam F, Roth J, Ha M Sci Rep. 2022; 12(1):12984.

PMID: 35906256 PMC: 9338066. DOI: 10.1038/s41598-022-16933-6.

Sequential Release of Paclitaxel and Imatinib from Core-Shell Microparticles Prepared by Coaxial Electrospray for Vaginal Therapy of Cervical Cancer.

Liu Z, Chen H, Lv F, Wang J, Zhao S, Li Y Int J Mol Sci. 2021; 22(16).

PMID: 34445466 PMC: 8395827. DOI: 10.3390/ijms22168760.

References

HEWLETT P . Measurement of the potencies of drug mixtures. Biometrics. 1969; 25(3):477-87. View

Laska E, Meisner M . Testing whether an identified treatment is best. Biometrics. 1989; 45(4):1139-51. View

Wu J, Houghton P . Assessing cytotoxic treatment effects in preclinical tumor xenograft models. J Biopharm Stat. 2010; 19(5):755-62. PMC: 2978919. DOI: 10.1080/10543400903105158. View

Kolb E, Gorlick R, Maris J, Keir S, Morton C, Wu J . Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011; 58(5):729-35. PMC: 3166415. DOI: 10.1002/pbc.23157. View

Snapinn S . Evaluating the efficacy of a combination therapy. Stat Med. 1987; 6(6):657-65. DOI: 10.1002/sim.4780060603. View

Hung H, Chi G, Lipicky R . Testing for the existence of a desirable dose combination. Biometrics. 1993; 49(1):85-94. View

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Lloyd H . Estimation of tumor cell kill from Gompertz growth curves. Cancer Chemother Rep. 1975; 59(2 Pt 1):267-77. View

Tan M, Fang H, Tian G, Houghton P . Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Stat Med. 2003; 22(13):2091-100. DOI: 10.1002/sim.1467. View

10.

Wu J, Tracey L, Davidoff A . Assessing interactions for fixed-dose drug combinations in tumor xenograft studies. J Biopharm Stat. 2012; 22(3):535-43. PMC: 4667736. DOI: 10.1080/10543406.2011.556285. View

11.

Kong M, Lee J . A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics. 2006; 62(4):986-95. DOI: 10.1111/j.1541-0420.2006.00579.x. View

12.

Hung H . Two-stage tests for studying monotherapy and combination therapy in two-by-two factorial trials. Stat Med. 1993; 12(7):645-60. DOI: 10.1002/sim.4780120704. View

13.

Machado S, Robinson G . A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Stat Med. 1994; 13(22):2289-309. DOI: 10.1002/sim.4780132202. View

14.

Straetemans R, OBrien T, Wouters L, van Dun J, Janicot M, Bijnens L . Design and analysis of drug combination experiments. Biom J. 2005; 47(3):299-308. DOI: 10.1002/bimj.200410124. View

15.

Kong M, Lee J . A semiparametric response surface model for assessing drug interaction. Biometrics. 2007; 64(2):396-405. PMC: 5096313. DOI: 10.1111/j.1541-0420.2007.00882.x. View

16.

Greco W, Bravo G, Parsons J . The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995; 47(2):331-85. View

17.

Hung H . Global tests for combination drug studies in factorial trials. Stat Med. 1996; 15(3):233-47. DOI: 10.1002/(SICI)1097-0258(19960215)15:3<233::AID-SIM167>3.0.CO;2-H. View

18.

Houghton P, Morton C, Tucker C, Payne D, Favours E, Cole C . The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2006; 49(7):928-40. DOI: 10.1002/pbc.21078. View